tirzepatide priority meds The FDA has granted review to a supplemental New Drug Application for talazoparib plus enzalutamide for patients with HRR gene-altered mCSPC, issuing a PDUFA target action date in Q4 of 2026 BLACK FRIDAY Specification:Contact for options 🧐Did you know? Gastroparesis

tirzepatide priority meds The FDA has granted review to a supplemental New Drug Application for talazoparib plus enzalutamide for patients with HRR gene-altered mCSPC, issuing a PDUFA target action date in Q4 of 2026 BLACK FRIDAY Specification:Contact for options 🧐Did you know? Gastroparesis

🧐Did you know? Gastroparesis affects an estimated 4% of adults, yet many live undiagnosed, mistaking it for indigestion. Symptoms like persistent nausea, bloating or feeling full too fast shouldn't be ignored. 🤢

As with semaglutide, Embody’s compounded tirzepatide has not been separately reviewed or approved by the FDA as a finished product, even though tirzepatide itself carries approved research as an individual compound

BLACK FRIDAY

Specification:Contact for options

Energy expectation: 70% to 85% of normal